

Detection of *bla*_{OXA-10} and *bla*_{OXA-48} Genes in *Pseudomonas aeruginosa* Clinical Isolates by Multiplex PCR

Aghdas Bibi Hashemi¹, Mahboobeh Nakhaei Moghaddam¹, Mohammad Mahdi Forghanifard², Ehsan Yousefi^{1*}

¹Department of Biology, Faculty of Science, Mashhad Branch, Islamic Azad University, Mashhad, Iran; ²Department of Biology, Faculty of Science, Damghan Branch, Islamic Azad University, Damghan, Iran

ARTICLE INFO

Original Article

Keywords: *Pseudomonas aeruginosa*, Multiplex PCR, *rpoD* gene, *bla*_{OXA-10} gene, *bla*_{OXA-48} gene

Received: 20 Apr. 2020

Received in revised form: 23 Aug. 2021

Accepted: 25 Sep. 2021

DOI: 10.52547/JoMMID.9.3.142

*Correspondence

Email: ehyaousefi@yahoo.com

Tel: +985138435050

Fax: +985138435050

© The Author(s)



ABSTRACT

Introduction: The rapidly increasing extended-spectrum β -lactamase-producing *Pseudomonas aeruginosa* is a threat to health. This study aims to detect the *rpoD* gene and *bla*_{OXA-10} and *bla*_{OXA-48} genes in imipenem-resistant *P. aeruginosa* clinical isolates simultaneously by multiplex polymerase chain reaction. **Methods:** Eighty-five culture plates were collected from patients suspected of *Pseudomonas* spp infection in Ghaem Hospital and Shahid Shourideh Clinic in Mashhad from January to February 2021. After biochemical identification of *P. aeruginosa* isolates and the measurement of antibiotic resistance, *bla*_{OXA-10}, *bla*_{OXA-48}, and *rpoD* genes were investigated by multiplex polymerase chain reaction in the imipenem-resistant isolates. **Results:** Of 82 *P. aeruginosa* isolates, 38 (46.34%) were resistant to imipenem, with the highest percentage to carbenicillin (69.5%). All imipenem-resistant *P. aeruginosa* isolates were confirmed by multiplex PCR using the primers that targeted the *rpoD* gene. Also, in multiplex PCR, among imipenem-resistant isolates, 10 (26.3%) and 9 (23.6%) had *bla*_{OXA-10} and *bla*_{OXA-48} genes, respectively. **Conclusion:** In addition to molecular identification of *P. aeruginosa*, the present study simultaneously detected *bla*_{OXA-10} and *bla*_{OXA-48} genes by multiplex PCR. Application of this multiplex PCR, rapid identification of patients, and timely treatment can reduce the β -lactamase gene prevalence in *P. aeruginosa* clinical isolates.

INTRODUCTION

Pseudomonas aeruginosa is an aerobic Gram-negative bacillus that causes an extensive range of opportunistic infections in humans. Infections due to this pathogen are frequently intense and health-threatening. *P. aeruginosa* infection is challenging to control and resolve since the causative bacteria are inherently resistant to many antimicrobial agents. The rapidly increasing extended-spectrum β -lactamase (ESBL)-producing *P. aeruginosa* bacteria poses a threat to public health [1]. This bacterium has an innate resistance to most antibiotic classes and can develop resistance against them even throughout treatment. Resistance expansion occurs through chromosomal mutations or horizontal transfer of resistance genes through plasmids, integrons, and transposons. The underlying mechanisms of the resistance are the efflux pump, alterations in outer membrane permeability, and carbapenemase and β -lactamase production. Epidemiological studies show that infections caused by resistant *P. aeruginosa* have increased illness, fatality, duration of stay in the hospital, and treatment cost [2].

Broad-spectrum penicillins, third and fourth descendant carbapenems, cephalosporins, monobactams, aminoglycosides, fluoroquinolones, and different antibiotics such as colistin are effective against *P. aeruginosa*. However, resistance mutations may appear and develop against all the anti-pseudomonal antibiotics [3].

A WHO report has shown vast rates of drug resistance in Gram-negative bacteria, with elevated illness and fatality. The *P. aeruginosa* clinical isolates quickly develop antibiotic resistance and spread in the hospital environment, making them fall under the WHO list of multidrug-resistant (MDR) bacteria [4].

P. aeruginosa has a main σ^{70} called *rpoD* that detects many promoters controlling the expression of housekeeping genes [5]. The OXA-type is one of the significant families of ESBLs. This family, classified into molecular class D and functional group 2d, can hydrolyze oxacillin. Unlike TEM and SHV, they are reported primarily in *P. aeruginosa* of the

Enterobacteriaceae family. Most of these enzymes are resistant to cephalothin and ampicillin with vast hydrolytic activity versus cloxacillin and oxacillin. However, they are poorly inhibited by clavulanic acid and cannot hydrolyze the fourth and fifth-generation cephalosporins; hence, they are not considered ESBLs [6]. Carbapenems are β -lactam antibiotics that are efficient against Gram-positive and Gram-negative bacteria. These antibiotics are resistant to cephalosporinases and penicillinases. However, some of the β -lactamase groups (A, B, and D) classification by Ambler can hydrolyze carbapenems [7].

Molecular methods can specifically identify the presence of Metallo β -lactamases (MBL) genes. The polymerase chain reaction (PCR) is one of the simplest and fastest methods. Other molecular methods used in MBL recognition are nucleotide sequence analysis, polyacrylamide gel electrophoresis, and isoelectric focusing [3].

OXA-10 and OXA-48 carbapenemase are crucial because OXA-10 hydrolyze poorly aztreonam and ceftriaxone, giving most microbes less susceptibility to these antimicrobials. Altogether, OXA-type β -lactamases are explosively increasing based on the amino acid sequence alterations; until now, 498 reports are available in the database [6]. The ESBLs OXA-11, OXA-14, OXA-16, OXA-17, OXA-19, and OXA-28 are relevant structurally to OXA-10. All of these ESBLs have been found in *P. aeruginosa* [8]. Also, in some cases, the OXA-48 has migrated into the *Enterobacteriaceae* and is becoming a significant cause of carbapenem resistance. The emergence of OXA enzymes that can confer resistance to carbapenems has converted these β -lactamases from a minor obstacle into a significant problem, reducing the clinical efficacy of carbapenems [9].

For the first time in Iran, the present study investigated the simultaneous presence of the *rpoD* gene and *bla_{OXA-10}* and *bla_{OXA-48}* genes in imipenem-resistant *P. aeruginosa* clinical isolates.

MATERIALS AND METHODS

Isolation and biochemical identification *P. aeruginosa*. Eighty-five culture plates from patients in Ghaem Hospital and Shahid Shourideh Clinic in Mashhad, suspected with *Pseudomonas* spp. infection was collected from January to February 2021 and transferred to the Microbiology Laboratory under sterile conditions on an ice pack. The identity of *P. aeruginosa* was confirmed by culturing the isolates on selective Cetrimide agar medium plates (Merck, Germany) followed by incubation at 42°C for 24 hours. The green-blue colonies were isolated and purified. After Gram staining, biochemical identification of *P. aeruginosa* was performed using biochemical tests, i.e., catalase, oxidase, methyl-red, SIM, Simmons citrate, culture in TSI agar, urea (Merck, Germany), and growth at 42°C and pigment output in Cetrimide agar medium [10].

Determination of antibiotic resistance patterns. The Kirby-Bauer disk diffusion method was performed for antibiotic susceptibility under aerobic conditions and according to the Clinical and Laboratory Standards Institute (CLSI, 2018) [11]. Antibiotic disks used for this purpose included Imipenem (IPM) (10 μ g), Cefazidime (CAZ) (30 μ g), and Carbenicillin (CB) (100 μ g) (Padtan Teb, Iran) [12-17].

Molecular identification and detection of genes. For this purpose, a multiplex PCR experiment was designed and performed. DNA extraction from IPM-resistant isolates was performed using the boiling technique. For this purpose, 3-4 new colonies from 24-hour old cultures were added to microtubes containing 200 μ L of distilled water, followed by incubation at 100 °C for 10 min. The suspensions were centrifuged at 9,500 \times g for 5 min in a BRK5424 rotor (Cleaver Scientific, United Kingdom), and the supernatants containing DNA were transferred to the new microtubes [18]. Identification of *P. aeruginosa* isolates was identified by primers complementary to the *rpoD* gene, and primers for *bla_{OXA-10}* and *bla_{OXA-48}* genes were used in IPM-resistant strains to identify β -lactamase enzymes producing isolates. The specificity of the primer sequences was checked by the Basic Local Alignment Search Tool (BLAST) at the NCBI site (<http://www.ncbi.nlm.nih.gov/>) and synthesized at a commercial company (Cinnagen, Iran) (Table 1).

Table 1. The sequence of primers used to amplify the *rpoD*, *bla_{OXA-10}* and, *bla_{OXA-48}* genes in multiplex PCR test

Primer pairs	Target	Primer sequence (5'→3')	Amplified product size (bp)	Reference
rpoD – F rpoD – R	rpoD	GGGCGAAGAAGGAAATGGTC CAGGTGGCGTAGGTGGAGAA	178	[19]
OXA – 10 – F OXA – 10 – R	OXA – 10 group	TCAACAAATCGCCAGAGAAG TCCCACACCAGAAAAACCAG	276	[20]
OXA – 48 – F OXA – 48 – R	OXA – 48 group	GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCAACCG	438	[21]

The multiplex PCR tests were performed in final 25 μ L volumes containing 12.5 μ L PCR master mix 2X (Pars Tous, Iran), 0.75 μ L of each primer with a concentration of 1 mM (CinnaGen, Iran), 2 μ L template

DNA, and 6 μ L sterile distilled water. The optimize thermocycler (Kyrattec, Korea) program consisted of 5 min initial denaturation at 95°C, 35 cycles of denaturation at 95°C for 30 s, annealing at 54°C for 30 s,

extension at 72°C for 30 s and a final extension at 72°C for 5 min., The PCR products were visualized by gel electrophoresis (Interlab, Italy) in 2% (w/v) agarose gel (Dena Gene, Iran) in TBE buffer (Pars Tous, Iran) stained with ethidium bromide (Merck, Germany) and photographed under UV in a Gel Documentation System (Cleaver Scientific, United Kingdom).

Statistical analysis. Statistical analysis of data was performed using SPSS software version 23 and

comparing the proportions with the Fisher's exact test at a probability level of five percent ($P < 0.05$).

RESULTS

Biochemical identification of *P. aeruginosa*. In this study, based on biochemical tests (Table 2), 82 *P. aeruginosa* isolates were identified among the 85 collected specimens

Table 2. Results of biochemical tests for detecting *P. aeruginosa* isolates.

Test	Gram stain	Citrate	Urease	Methyl Red	Grow at 42°C	Motility	Indole	Sugar fermentation	Catalase	Oxidase
Result	Negative	+	-	-	+	+	-	-	+	+

Antibiotic susceptibility pattern. Out of 82 *P. aeruginosa* isolates, 38 (46.34%) were resistant to IPM. The isolates were categorized as "susceptible,"

"intermediate," or "resistant" to the antibiotics IPM, CAZ, and CB (Table 3).

Table 3. Antibiotic susceptibility pattern among 82 *P. aeruginosa* isolates

Antibiotic	Susceptibility (%)		
	Susceptible	Intermediate	Resistant
IPM	47.56	6.09	46.34
CAZ	21.9	17.7	60.9
CB	20.7	9.7	69.5

IPM, Imipenem; CAZ, Ceftazidime; CB, Carbenicillin

Figure 1 shows the resistance to CB and CAZ antibiotics among the susceptible and resistant isolates to imipenem. As shown in the diagram, based on the statistical analysis performed, the resistance rates to CB and CAZ antibiotics among imipenem-resistant isolates

were significantly higher than imipenem-susceptible isolates ($p < 0.0001$), indicating the possibility of simultaneous transfer of antibiotic resistance genes. The resistance rates to CB and CAZ among imipenem-resistant isolates were 100% (Fig.1).




Fig. 1. Resistance pattern to CB and CAZ among susceptible and resistant isolates to imipenem. CAZ, Ceftazidime; CB, Carbenicillin

Molecular identification of isolates and genes. All imipenem-resistant *P. aeruginosa* isolates ($n=38$) were confirmed by multiplex PCR amplifying the *rpoD* gene. Also, in multiplex PCR, among imipenem-resistant isolates had 10 (26.3%) *bla*_{OXA-10} gene and 9 (23.6%)

*bla*_{OXA-48} gene. The amplicons size yielded by the multiplex PCR for the *rpoD*, *bla*_{OXA-10}, and *bla*_{OXA-48} genes were similar to the standard samples, i.e., 178, 276, and 438 bp, respectively (Fig. 2).




Fig 2. Gel electrophoresis of multiplex PCR products after amplification of *rpoD*, *bla_{OXA-10}*, and *bla_{OXA-48}* genes for imipenem-resistant *P. aeruginosa* isolates along with the 100-bp DNA size marker. Lanes 1-6, specimens; L, 100-bp DNA Ladder- 100-1000 bp (Sinaclone, Iran); C+, positive control; C-, negative control.

DISCUSSION

P. aeruginosa is an opportunistic and nosocomial pathogen that can cause several infections with high fatality in patients, especially in immunocompromised individuals hospitalized in hospitals [22-24]. Therefore, a reliable method is required to detect this pathogen as rapidly as possible and track the genes involved in antibiotic resistance.

MBLs are significant because of conferring resistance against carbapenems (imipenem, meropenem, biapenem, and ertapenem), the most efficacious antibiotics used against *P. aeruginosa*. The prevalence of carbapenem resistance in *P. aeruginosa*, which plays a crucial role in nosocomial infections, is a severe threat in treating conditions caused by this bacterium [25, 26].

This study aimed to appraise the antimicrobial resistance pattern and detect the frequency of *bla_{OXA-10}* and *bla_{OXA-48}* genes alongside the *rpoD* gene in *P. aeruginosa* clinical isolates.

Most isolates in this study showed multiple resistance to various antibiotics, including IMP (46.34%), CAZ (60.9%), and CB (69.5%), with rates higher than those reported in China [27] but lower than in India [28]. These variations might be due to differences in antibiotic use in different countries (29). A survey on *P. aeruginosa* isolates from respiratory and urinary secretions reported the highest resistance to aztreonam and imipenem [30]. In another survey on *P. aeruginosa* blood isolates, the frequency of imipenem-resistant strains was 34% [31]. The achievements of the present study are similar to the findings of the above studies. In a study, the frequency of carbapenem-resistant in *P. aeruginosa* clinical isolates was 24% [32]. A 10-year longitudinal surveillance study in Taiwan, among 78 non-duplicated imipenem-resistant *P. aeruginosa* isolates collected from patients with blood infections, reported an imipenem resistance of 5.9% [33]. A possible cause of the difference in the results of these studies with the present study might be extended

hospitalization at the intensive care unit (≥ 29 days) that can lead to the acquisition of carbapenem resistance [34].

In Our study, all imipenem-resistant *P. aeruginosa* isolates (n=38) were confirmed by amplifying the *rpoD* gene in multiplex PCR. Also, in multiplex PCR, among imipenem-resistant isolates, 10 (26.3%) and 9 (23.6%) had *bla_{OXA-10}* and *bla_{OXA-48}* genes, respectively. In conclusion, a high prevalence of *bla_{OXA-10}* and *bla_{OXA-48}* genes was observed in this study, and imipenem was the effective agent against *P. aeruginosa* isolates.

Similar studies like the present have used *rpoD* gene amplification as a rapid, inexpensive, and reliable method for the molecular identification of *P. aeruginosa* [35-37]. In a similar study, of 50 imipenem-resistant isolates, 18 (36%) had the *bla_{OXA-10}* gene [12]. In two other studies, *bla_{OXA-10}* was detected in 22 (32.3 %) and 12 (27.27%) imipenem-resistant isolates [13, 14]. In Tehran, 83.95% of *P. aeruginosa* isolates in the Burn Unit of Shahid Motahari Hospital showed resistance to imipenem, and 83.70% contained *bla_{OXA-48}* [15]; the imipenem resistance rate and isolates percentage containing the *bla_{OXA-48}* gene was more than the present study. This discrepancy may be due to different clinical specimens. Although the resistance mechanisms to imipenem in isolates are different, the results of the present study and similar researches can reverberate that the OXA-type β -lactamases can efficiently hydrolyze carbapenem.

Recent reports indicate a high prevalence of ESBLs, especially OXA-types, in hospitalized patients in various cities of Iran [17, 38, 39]. Therefore, surveillance programs must be adopted to prevent the spread of these worrisome resistance genes [26]. Application of this multiplex PCR, rapid identification of patients, and timely treatment can reduce the β -lactamase gene prevalence in *P. aeruginosa* clinical isolates.

Further studies are required to test the specificity of this multiplex PCR with DNA from other *Pseudomonas* species and other bacteria.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest associated with this manuscript.

ACKNOWLEDGMENT

We thank the Microbiology Laboratory of Ghaem Hospital and Shahid Shourideh Clinic, Islamic Azad University of Mashhad, and those who helped us in this research. We had no sources of financial support.

REFERENCES

1. Bahrami M, Mohammadi-Sichani M, Vajihe K. Prevalence of *SHV*, *TEM*, *CTX-M* and *OXA-48* β -Lactamase genes in clinical isolates of *Pseudomonas aeruginosa* in Bandar-Abbas, Iran. *Avicenna J Clin Microbiol Infect*. 2018; 5 (4): 86-90.
2. Ullah W, Qasim M, Rahman H, Jie Y, Muhammad N. Beta-lactamase-producing *Pseudomonas aeruginosa*: Phenotypic characteristics and molecular identification of virulence genes. *J Chin Med Assoc*. 2017; 80 (3): 173-7.
3. Vural E, Delialioglu N, Ulger ST, Emekdas G, Serin MS. Phenotypic and molecular detection of the metallo-beta-lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates from clinical samples. *Jundishapur J Microbiol*. 2020; 13 (2): e90034.
4. Athreya AG, Shareef MI, Gopinath SM. Silver Nanoparticles from Cow's Milk to Combat Multidrug-resistant gram-negative bacteria from clinical isolates. *Proc Natl Acad Sci India Sect B Biol Sci*. 2020; 90 (4): 861-71.
5. Potvin E, Sanschagrin F, Levesque R.C. Sigma factors in *Pseudomonas aeruginosa*. *FEMS Microbiol Rev*. 2008; 32 (1): 38-55.
6. Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The growing genetic and functional diversity of extended spectrum beta-lactamases. *BioMed Res Int*. 2018; 2018: 1-14.
7. Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, et al. β -Lactamases and β -Lactamase inhibitors in the 21st century. *J Mol Biol*. 2019; 431 (18): 3472-500.
8. Antunes NT, Fisher JF. Acquired class D β -Lactamases. *Antibiotics (Basel)*. 2014; 3 (3): 398-434.
9. Evans BA, Amyes SG. OXA β -lactamases. *Clin Microbiol Rev*. 2014; 27 (2): 241-63.
10. Bhuiya M, Sarkar MKI, Sohag MH, Ali H, Roy CK, Akther L, et al. Enumerating antibiotic susceptibility patterns of *Pseudomonas aeruginosa* isolated from different sources in Dhaka city. *Open Microbiol J*. 2018; 12: 172-80.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Document M100. CLSI, Wayne, PA, USA, 2018.
12. Pakbaten Toupkanlou S, Najar Peerayeh S, Pirhajati Mahabadi R. Class A, and D Extended-Spectrum β -Lactamases in imipenem resistant *Pseudomonas aeruginosa* isolated from burn patients in Iran. *Jundishapur J Microbiol*. 2015; 8 (8): e59888.

13. Farajnia, S. OXA-10, and OXA-2 ESBLs among multidrug-resistant *Pseudomonas aeruginosa* isolates from North West of Iran. *Prog Biol Sci*. 2017; 7 (2): 191-7.
14. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother*. 2001; 45 (2): 480-4.
15. Tarafdar F, Jafari, B, Azimi. Evaluating the antimicrobial resistance patterns and molecular frequency of bla_{OXA-48} and bla_{GES-2} genes in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* strains isolated from burn wound infection in Tehran, Iran. *New Microbes New Infect*. 2020; 37: 100686.
16. Gutierrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, et al. Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* isolates from Spanish hospitals. *Antimicrob Agents Chemother*. 2007; 51 (12): 4329-35.
17. Aria M, Farajnia S, Ahdi Khosroshahi S, Naghilli B, Farajnia H, Sanjari A, et al. OXA-10 and OXA-2 ESBLs among multidrug-resistant *Pseudomonas aeruginosa* isolates from North West of Iran. *Prog Biol Sci*. 2017; 7 (2): 191-7.
18. Sameni N, Shahbeik M, Dabiri H. Investigating the presence of type IV pilin subgenus in *Pseudomonas aeruginosa* isolated from clinical and non-clinical samples. *Iran J Med Microbiol*. 2019; 13 (3): 164-74.
19. Kaluzny K, Abeyrathne PD, Lam JS. Coexistence of two distinct versions of O-antigen polymerase, Wzy-alpha, and Wzy-beta, in *Pseudomonas aeruginosa* serogroup O2 and their contributions to cell surface diversity. *J Bacteriol*. 2007; 189 (11): 4141-52.
20. Maurya AP, Dhar D, Basumatary MK, Paul D, Ingti B, Choudhury D, et al. Expansion of highly stable bla_{OXA-10} β -lactamase family within diverse host range among nosocomial isolates of Gram-negative bacilli within a tertiary referral hospital of Northeast India. *BMC Res Notes*. 2017; 10 (1): 145.
21. Hosseinzadeh Z, Sedigh Ebrahim-Saraie H, Sarvari J, Mardaneh J, Dehghani B, Rokni-Hosseini SMH, et al. Emerge of bla_{NDM-1} and bla_{OXA-48-like} harboring carbapenem-resistant *Klebsiella pneumoniae* isolates from hospitalized patients in southwestern Iran. *J Chin Med Assoc*. 2018. 81 (6): 536-40.
22. Adjei C.B, Govinden U, Moodley K, Essack S. Molecular characterization of multidrug-resistant *Pseudomonas aeruginosa* from a private hospital in Durban, South Africa. *S Afr J Infect Dis*. 2018; 33 (2): 38-41.
23. Rodrigues YC, Furlaneto IP, Maciel AHP, Quaresma AJPG, de Matos ECO, Conceição ML, et al. High prevalence of atypical virulotype and genetically diverse background among *Pseudomonas aeruginosa* isolates from a referral hospital in the Brazilian Amazon. *PLoS One*. 2020; 15 (9): e0238741.
24. Moradali MF, Ghods S, Rehm BH. *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front Cell Infect Microbiol*. 2017; 7: 39.
25. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing VIM-1, a novel

transferable metallo-beta-lactamase. Clin Infect Dis. 2000; 31 (5): 1119-25.

26. Luzzaro F, Endimiani A, Docquier JD, Mugnaioli C, Bonsignori M, Amicosante G, et al. Prevalence and characterization of Metallo- β -lactamases in clinical isolates of *Pseudomonas aeruginosa*. Diagn Microbiol Infect Dis. 2004; 48 (2): 131-5.

27. Gu B, Tong M, Zhao W, Liu G, Ning M, Pan S. Prevalence and characterization of class I integrons among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolates from patients in Nanjing, China. J Clin Microbiol. 2007; 45 (1): 241-3.

28. Uma Karthika R, Srinivasa Rao R, Sahoo S, Shashikala P, Kanungo R, Jayachandran S, et al. Phenotypic and genotypic assays for detecting the prevalence of metallo-beta-lactamases in clinical isolates of *Acinetobacter baumannii* from a South Indian tertiary care hospital. J Med Microbiol. 2009; 58 (Pt 4): 430-5.

29. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant *Acinetobacter species* in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000; 31 (1): 101-6.

30. Zaranza AV, Morais FC, do Carmo MS, de Mendonça Marques A, Andrade-Monteiro C, et al. Antimicrobial susceptibility, biofilm production and adhesion to HEp-2 cells of *Pseudomonas aeruginosa* strains isolated from clinical samples. J Biomat Nanobiotechnol. 2013; 4 (1): 98.

31. Renata Gomes Franco M, Hehl CaiaffaFilho H, Nascimento Burattini M, Rossi F. Metallo- beta-lactamases among imipenem-resistant *Pseudomonas aeruginosa* in a Brazilian university hospital. Clin Sci. 2010; 65 (9): 825-9.

32. Kateete DP, Nakanjako R, Namugenyi J, Erume J, Joloba ML, Najjuka CF. Carbapenem resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* at Mulago Hospital

in Kampala, Uganda (2007-2009). Springerplus. 2016; 5 (1): 1308.

33. Kao CY, Chen SS, Hung KH, Wu HM, Hsueh PR, Yan JJ, et al. Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant *Pseudomonas aeruginosa* isolated from patients with bloodstream infections in Taiwan. BMC Microbiol. 2016; 16 (1): 107.

34. Labaste F, Grossac J, Bounes FV, Conil JM, Ruiz S, Seguin T, et al. Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study. Eur J Clin Microbiol Infect Dis. 2019; 38 (12): 1-9.

35. Girard L, Lood C, Rokni-Zadeh H, van Noort V, Lavigne R, De Mot R. Reliable Identification of Environmental *Pseudomonas* Isolates Using the *rpoD* Gene. Microorganisms. 2020; 8 (8): 1166.

36. Sanchez D, Matthijs S, Gomila M, Tricot C, Mulet M, Garcia-Valdes E, et al. *rpoD* gene pyrosequencing for the assessment of *Pseudomonas* Diversity in a water sample from the Woluwe River. Appl Environ Microbiol. 2014; 80 (15): 4738-44.

37. Galdino ACM, Viganor L, de Castro AA, da Cunha EFF, Mello TP, Mattos LM, et al. Disarming *Pseudomonas aeruginosa* virulence by the inhibitory action of 1,10-phenanthroline-5,6-dione-based compounds: elastase B (LasB) as a chemotherapeutic target. Front Microbiol. 2019; 10: 1701.

38. Danel F, Hall LM, Gur D, Livermore DM. OXA-14, another extended spectrum variant of OXA-10 (PSE-2) beta-lactamase from *Pseudomonas aeruginosa*. Antimicrob Agents Chemother. 1995; 39 (8): 1881-4.

39. Shakibaie MR, Shahcheraghi F, Hashemi A, Adeli NS. Detection of *TEM*, *SHV*, and *PER* type extended-spectrum β -lactamase genes among clinical strains of *Pseudomonas aeruginosa* isolated from burnt patients at Shafa-Hospital, Kerman, Iran. Iran J Basic Med Sci. 2008; 11 (2): 104-11.

Cite this article:

Hashemi AB, Nakhaei Moghaddam M, Forghanifard MM, Yousefi E. Detection of *bla_{OXA-10}* and *bla_{OXA-48}* genes in *Pseudomonas aeruginosa* clinical isolates by multiplex PCR. J Med Microbiol Infect Dis, 2021; 9 (3): 142-147. DOI: 10.52547/JoMMID.9.3.142